Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421

Blood

Volumn 107, Issue 4, 2006, Pages 1315-1324

  Becton, David ^b   Dahl, Gary V ^a   Ravindranath, Yaddanapudi ^b   Chang, Myron N ^b   Behm, Fred G ^b   Raimondi, Susana C ^b   Head, David R ^b   Stine, Kimo C ^b   Lacayo, Norman J ^b   Sikic, Branimir Ivan ^b   Arceci, Robert J ^b   Weinstein, Howard ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; GLYCOPROTEIN P; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BACTEREMIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CEREBELLAR ATAXIA; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR; DRUG MEGADOSE; FEVER; GENE OVEREXPRESSION; HLA SYSTEM; HUMAN; HUMAN TISSUE; INFECTION; MYCOSIS; NEUROTOXICITY; NEUTROPENIA; PATIENT; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEPSIS; SIBLING; SURVIVAL;

EID: 32644443640     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2004-08-3218     Document Type: Article

References (40)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
2. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-1062.
3. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood: Pediatric Oncology Group. N Engl J Med. 1996;334:1428-1434.
4. Abella E, Ravindranath Y. Therapy for childhood acute myeloid leukemia: role of allogeneic bone marrow transplantation. Curr Oncol Rep. 2000;2:529-538.
5. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97:56-62.
6. Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 2001;15:348-354.
7. Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001;19:2705-2713.
8. Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93:4116-4124.
9. Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998;16:872-881.
10. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88:2841-2851.
11. Bishop JF, Matthews JP, Young GA, Bradstock Lowenthal RM. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma. 1998;28:315-327.
12. Burnett AK, Goldstone AH, Stevens RM, et al. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRCAML10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet. 1998;351:700-708.
13. Burke PJ, Vaughan WP, Karp JE. A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation. Blood. 1980;55:960-968.
14. Burnett AK. Treatment of acute myeloid leukaemia in younger patients. Best Pract Res Clin Haematol. 2001;14:95-118.
15. Sonneveld P, List AF. Chemotherapy resistance in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14:211-233.
16. Dean M. The human ATP-binding cassette (ABC) transporter superfamily. Bethesda, MD: National Center for Biotechnology Information; 2002.
17. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am. 1995;9:363-382.
18. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999;94:1086-1099.
19. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: A Southwest Oncology Group study. Blood. 1997;89:3323-3329.
20. Sievers EL, Smith FO, Woods WG, et al. Cell surface expression of the multidrug resistance Pglycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group. Leukemia. 1995;9:2042-2048.
21. Dahl GV, Lacayo NJ, Brophy N, et al. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. J Clin Oncol. 2000;18:1867-1875.
22. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol. 1992;10:1635-1642.
23. Lacayo NJ, Lum BL, Becton DL, et al. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia. 2002;16:920-927.
24. Broxterman HJ, Sonneveld P, Feller N, et al. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood. 1996;87:4809-4816.
25. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996;56:3010-3020.
26. Kessel D, Beck WT, Kukuruga D, Schulz V. Characterization of multidrug resistance by fluorescent dyes. Cancer Res. 1991;51:4665-4670.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:475-481.
28. Peto R PJ. Asymptotically efficient rank invariant test procedures. J R Stat Soc. 1972;135:185-206.
29. Young IT. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem. 1977;25:935-941.
30. Leith CP, Chen IM, Kopecky KJ, et al. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. Blood. 1995;86:2329-2342.
31. Ino T, Miyazaki H, Isogai M, et al. Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome. Leukemia. 1994;8:1492-1497.
32. Stevens RF, Hann IM, Wheatley K, et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol. 1998;101:130-140.
33. van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ, et al. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood. 2001;97:3605-3611.
34. Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie JP. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood. 1999;94:1046-1056.
35. Ross DD, Karp JE, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood. 2000;96:365-368.
36. van den Heuvel-Eibrink MM, Sonneveld P, Pieters R. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther. 2000;38:94-110.
37. van den Heuvel-Eibrink MM, Wiemer EA, Prins A, et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia. 2002;16:833-839.
38. Diah SK, Smitherman PK, Aldridge J, et al. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Res. 2001;61:5461-5467.
39. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci. 2001;58:931-959.
40. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98:3212-3220.